Grimes & Company’s Amicus Therapeutics FOLD Stock Holding History

Grimes & Company’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,987	Closed	-$303K	–	456
2026 Q1	$303K	Sell	20,987 -3,396	-14%	-$48.7K	0.01%	354
2025 Q4	$347K	Hold	24,383	–	–	0.01%	360
2025 Q3	$192K	Buy	24,383 +456	+2%	+$3.25K	﹤0.01%	441
2025 Q2	$137K	Buy	23,927 +717	+3%	+$4.63K	﹤0.01%	406
2025 Q1	$189K	Sell	23,210 -1,060	-4%	-$9.81K	0.01%	357
2024 Q4	$229K	Hold	24,270	–	–	0.01%	348
2024 Q3	$259K	Hold	24,270	–	–	0.01%	318
2024 Q2	$241K	Buy	24,270 +47	+0.2%	+$482	0.01%	305
2024 Q1	$285K	Sell	24,223 -145	-0.6%	-$1.85K	0.01%	275
2023 Q4	$346K	Sell	24,368 -283	-1%	-$3.21K	0.01%	251
2023 Q3	$300K	Buy	24,651 +412	+2%	+$5.32K	0.01%	242
2023 Q2	$304K	Buy	24,239 +43	+0.2%	+$510	0.01%	241
2023 Q1	$268K	Buy	+24,196	New	+$298K	0.01%	249

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Grimes & Company's FOLD Position: Q2 2026 in Review

Grimes & Company sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 20,987 shares — an estimated $303K sold.

Grimes & Company first reported a position in FOLD in Q1 2023 and held it in 13 quarters. The position peaked at $347K in Q4 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Grimes & Company reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Grimes & Company sold 20,987 Amicus Therapeutics shares in Q2 2026, an estimated $303K.
Grimes & Company first reported a position in Amicus Therapeutics in Q1 2023 and held it in 13 quarters.
Grimes & Company's Amicus Therapeutics position peaked at $347K in Q4 2025.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.